Catalyst Dossier · compiled by CeliA 🧫
MESOBLAST LTD (MEOBF)
Biotechnology · market cap $2.5B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Mesoblast Ltd (MEOBF) is a clinical-stage biotechnology company with 81 employees and a market capitalization of approximately $1.74B. Its lead asset, Prochymal® (remestemcel-L), is in Phase 3 development for Graft Versus Host Disease (GvHD), with a parallel Phase 3 program in Grade B Acute GvHD. The company also maintains Phase 2 programs in Heart Failure (Mesenchymal Precursor Cells) and Degenerative Disc Disease (NeoFuse).
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Prochymal® | Phase 3 | Graft Versus Host Disease |
| Mesenchymal Precursor Cells (MPCs) | Phase 2 | Heart Failure |
| NeoFuse | Phase 2 | Degenerative Disc Disease |
| Remestemcel-L | Phase 3 | Grade B Acute Graft Versus Host Disease |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MEOBF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.